<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939987</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00074034</org_study_id>
    <nct_id>NCT04939987</nct_id>
  </id_info>
  <brief_title>Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy</brief_title>
  <official_title>Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will address the gaps in research of non-opioid postoperative pain management for&#xD;
      prostatectomies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will conduct a randomized control double-blind clinical trial to evaluate an&#xD;
      opioid versus a non-opioid pathway of gabapentin, ketorolac, and acetaminophen in treating&#xD;
      postoperative pain following robot-assisted radical prostatectomy (RARP).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Pain Score</measure>
    <time_frame>1 hour before surgery</time_frame>
    <description>Pain scores will be collected using the Visual Analogue Pain Score and measured on a scale of 0-10, with 0 being no pain 10 being the worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Score</measure>
    <time_frame>Baseline</time_frame>
    <description>Pain scores will be collected using the Visual Analogue Pain Score and measured on a scale of 0-10, with 0 being no pain 10 being the worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Score</measure>
    <time_frame>Day 1</time_frame>
    <description>Pain scores will be collected using the Visual Analogue Pain Score and measured on a scale of 0-10, with 0 being no pain 10 being the worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Score</measure>
    <time_frame>Day 3</time_frame>
    <description>Pain scores will be collected using the Visual Analogue Pain Score and measured on a scale of 0-10, with 0 being no pain 10 being the worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analogue Pain Score</measure>
    <time_frame>Day 7</time_frame>
    <description>Pain scores will be collected using the Visual Analogue Pain Score and measured on a scale of 0-10, with 0 being no pain 10 being the worst pain imaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of medication used</measure>
    <time_frame>1 hour before surgery</time_frame>
    <description>measure opioid utilization by surveying patients on their usage while collecting their pain scores - Opioid oral morphine milligram equivalents (OMEQ) will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of medication used</measure>
    <time_frame>Baseline</time_frame>
    <description>measure opioid utilization by surveying patients on their usage while collecting their pain scores - Opioid oral morphine milligram equivalents (OMEQ) will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of medication used</measure>
    <time_frame>Day 1</time_frame>
    <description>measure opioid utilization by surveying patients on their usage while collecting their pain scores - Opioid oral morphine milligram equivalents (OMEQ) will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of medication used</measure>
    <time_frame>Time of Discharge postoperative up to Day 3</time_frame>
    <description>measure opioid utilization by surveying patients on their usage while collecting their pain scores - Opioid oral morphine milligram equivalents (OMEQ) will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid-Related Symptom Distress Scale (ORSDS)</measure>
    <time_frame>1 hour before surgery</time_frame>
    <description>4-point scale that evaluates 12 symptoms in 3 symptom categories including frequency, severity, and bothersomeness. The ORSDS may be used to calculate a symptom-specific score, which is the average of the 3 symptom distress dimensions and range from 0 to 4. The composite ORSDS score is the mean of all 12 symptom-specific scores. Composite ORSDS scores range from 0 to 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid-Related Symptom Distress Scale (ORSDS)</measure>
    <time_frame>Baseline</time_frame>
    <description>4-point scale that evaluates 12 symptoms in 3 symptom categories including frequency, severity, and bothersomeness. The ORSDS may be used to calculate a symptom-specific score, which is the average of the 3 symptom distress dimensions and range from 0 to 4. The composite ORSDS score is the mean of all 12 symptom-specific scores. Composite ORSDS scores range from 0 to 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid-Related Symptom Distress Scale (ORSDS)</measure>
    <time_frame>Day 1</time_frame>
    <description>4-point scale that evaluates 12 symptoms in 3 symptom categories including frequency, severity, and bothersomeness. The ORSDS may be used to calculate a symptom-specific score, which is the average of the 3 symptom distress dimensions and range from 0 to 4. The composite ORSDS score is the mean of all 12 symptom-specific scores. Composite ORSDS scores range from 0 to 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid-Related Symptom Distress Scale (ORSDS)</measure>
    <time_frame>Day 3</time_frame>
    <description>4-point scale that evaluates 12 symptoms in 3 symptom categories including frequency, severity, and bothersomeness. The ORSDS may be used to calculate a symptom-specific score, which is the average of the 3 symptom distress dimensions and range from 0 to 4. The composite ORSDS score is the mean of all 12 symptom-specific scores. Composite ORSDS scores range from 0 to 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid-Related Symptom Distress Scale (ORSDS)</measure>
    <time_frame>Day 7</time_frame>
    <description>4-point scale that evaluates 12 symptoms in 3 symptom categories including frequency, severity, and bothersomeness. The ORSDS may be used to calculate a symptom-specific score, which is the average of the 3 symptom distress dimensions and range from 0 to 4. The composite ORSDS score is the mean of all 12 symptom-specific scores. Composite ORSDS scores range from 0 to 4.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Radical Prostatectomies</condition>
  <arm_group>
    <arm_group_label>Opioid Control Cohort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One treatment selected:&#xD;
Tramadol (50mg) Hydrocodone-Acetaminophen (2.5mg/325mg) Oxycodone-Acetaminophen (2.5mg/325mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multimodal Approach:&#xD;
Gabapentin (100mg TID) Ketorolac (15mg q6) Acetaminophen (1mg IV q6) Ketamine (1.5mg/kg) Ketorolac tromethamine (15mg or 30mg Q4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Opioid Control Cohort (One treatment selected)</description>
    <arm_group_label>Opioid Control Cohort</arm_group_label>
    <other_name>Opioid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Experimental Cohort (Multimodal Approach)</description>
    <arm_group_label>Experimental Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone-Acetaminophen</intervention_name>
    <description>Opioid Control Cohort (One treatment selected)</description>
    <arm_group_label>Opioid Control Cohort</arm_group_label>
    <other_name>Opioid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone-Acetaminophen</intervention_name>
    <description>Opioid Control Cohort (One treatment selected)</description>
    <arm_group_label>Opioid Control Cohort</arm_group_label>
    <other_name>Opioid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Experimental Cohort (Multimodal Approach)</description>
    <arm_group_label>Experimental Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Experimental Cohort (Multimodal Approach)</description>
    <arm_group_label>Experimental Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac tromethamine</intervention_name>
    <description>Experimental Cohort (Multimodal Approach)</description>
    <arm_group_label>Experimental Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Experimental Cohort (Multimodal Approach)</description>
    <arm_group_label>Experimental Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All men ages 40-75 undergoing bilateral robot assisted radical prostatectomy (RARP)&#xD;
             with bilateral lymph node dissection with low-intermediate to high-risk localized&#xD;
             prostate cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies to any medication involved in the study&#xD;
&#xD;
          -  T4 prostate cancer&#xD;
&#xD;
          -  incarcerated persons&#xD;
&#xD;
          -  chronic narcotic dependence&#xD;
&#xD;
          -  any current prescription for narcotics&#xD;
&#xD;
          -  any surgery in the past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ram Pathak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ram Pathak, MD</last_name>
    <phone>336-716-3270</phone>
    <email>rpathak@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caleb Bercu</last_name>
    <phone>(305) 680-4409</phone>
    <email>cbercu@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wake Forest Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ram Pathak, MD</last_name>
      <phone>336-716-3270</phone>
      <email>rpathak@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caleb Bercu</last_name>
      <phone>(305) 680-4409</phone>
      <email>cbercu@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ram Pathak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioids</keyword>
  <keyword>postoperative pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

